Navigation Links
ADVENTRX Pharmaceuticals Announces Plans for Remainder of 2009
Date:6/29/2009

- Final manufacturing activities for ANX-530 NDA re-started

SAN DIEGO, June 29 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced its plans for the remainder of 2009.

Following the financing that closed earlier this month, ADVENTRX has re-started the final manufacturing activities related to submitting an NDA for ANX-530. In addition, the Company will continue to evaluate the data from its recently-completed bioequivalence study of ANX-514 and plans to seek a meeting with the FDA to discuss the results. For the near-term, the Company intends to maintain its cost-efficient and flexible infrastructure by engaging consultants on a project basis and outsourcing substantially all of its development activities to specialized vendors and contract development organizations.

"We believe ANX-530 has a clear path to NDA submission that involves a small number of remaining activities and our recent financing allowed us to very quickly re-start much of that work, as well as to continue to evaluate the best path forward for ANX-514. An update on our NDA submission timeline will be provided as critical activities are completed; however, our goal is to submit the NDA around the end of 2009," said Brian M. Culley, Chief Business Officer at ADVENTRX. "The extensive market research and analysis we commissioned from independent third-parties suggests there is an attractive market opportunity in the U.S. for ANX-530, which market can be accessed with a small, cost-effective sales organization."

"Given the limited cost of the remaining development activities leading to an NDA submission, we determined that the value of ANX-530 to our stockholders would be maximized by raising the necessary capital to move forward independently. This decision and our ability to file the NDA r
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
3. ADVENTRX Pharmaceuticals to Present at the 20th Annual Bear Stearns Healthcare Conference
4. ADVENTRX Announces ANX-514 Clinical Development Plan Affirmed by the FDA
5. ADVENTRX Pharmaceuticals to Present at the ThinkEquity Partners Fifth Annual Growth Conference
6. ADVENTRX Pharmaceuticals to Present at the 2007 UBS Global Life Sciences Conference
7. ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference
8. ADVENTRX Pharmaceuticals to Present at the 2007 BIOInvestor Forum
9. ADVENTRX Appoints Vice President of Commercialization
10. ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results
11. ADVENTRX Announces Consolidation of Clinical and Management Positions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... positions Company to ... quarter of this year, ROCKVILLE, Md., Sept. 19 ... has completed enrollment of healthy,volunteers in a Phase IIa ... vaccine. The Phase IIa randomized, placebo,controlled clinical trial is ...
... Thirty seven medical,experts in psychiatry from across the ... urgent action to optimize services for people with ... or bipolar,disorder(i)., Professor W. Wolfgang Fleischhacker, principal ... Mental Disorders: Clinical,Policy, and Research Challenges which was ...
... NEP ),today announced that the Company has received ... indicating that the Company is not in,compliance with certain ... the AMEX Company Guide. Specifically, AMEX noted the,Company,s failure ... relating to stockholders, equity of less than $6,000,000 and ...
Cached Biology Technology:Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial 2Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial 3Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial 4Global Psychiatrists Unite to Improve Services in Mental Health 2Global Psychiatrists Unite to Improve Services in Mental Health 3Nephros Receives Non-Compliance Notification from AMEX 2Nephros Receives Non-Compliance Notification from AMEX 3
(Date:11/21/2014)... 2014 C-Labs LLC, a leading provider of ... (IoT), today announced the appointment of John Traynor ... a strategic advisor to the firm, Mr. Traynor will ... is based out of the C-Labs office in ... Chris Muench , Chief Executive Officer. Photo ...
(Date:11/18/2014)... -- The Parenteral Drug Association (PDA) today confirmed that seven ... at least seven more will participate in the upcoming 2014 ... in Washington D.C. , Dec. 2-4. ... from the regulatory agencies in the United States ... effort to help advance the use of metrics in the ...
(Date:11/11/2014)... 11, 2014  Forensicon, Inc., a Chicago ... to announce the promotion of Yaniv Schiff ... Forensics. In Schiff,s new role as Director, he will ... digital forensics examiners and provide leadership within the company,s ... http://photos.prnewswire.com/prnh/20141110/157719 Schiff joined Forensicon ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2
... at the Ruhr-Universitt Bochum (RUB) have launched a new ... in promoting neuronal survival. The team of Prof Dr ... Department of Molecular Cell Biology, is looking for new ... Fox Foundation finances this research project with 125,000 US ...
... Discovery Fund (LSDF) today announced $1.1 million in ... and non-profit organizations to foster the translation of ... marketplace. Two of the five new ... invented within Washington-based companies. HeatFlow Technologies (principal investigator ...
... Tech leaders close out 2013 with beneficial ... (NASDAQ: SYMC ), Avago Technologies Limited (NASDAQ: ... ) and Apple Inc. (NASDAQ: AAPL) NXT-ID, Inc. ... Its Newly Formed Advisory Board And Shows First Images of ...
Cached Biology News:Life Sciences Discovery Fund announces R&D grants 2Markets Poised for Healthy 2014 as Biometrics Makes Strides in Technology Sector - Company Strengthens Board with Industry's Top Leaders 2Markets Poised for Healthy 2014 as Biometrics Makes Strides in Technology Sector - Company Strengthens Board with Industry's Top Leaders 3Markets Poised for Healthy 2014 as Biometrics Makes Strides in Technology Sector - Company Strengthens Board with Industry's Top Leaders 4Markets Poised for Healthy 2014 as Biometrics Makes Strides in Technology Sector - Company Strengthens Board with Industry's Top Leaders 5Markets Poised for Healthy 2014 as Biometrics Makes Strides in Technology Sector - Company Strengthens Board with Industry's Top Leaders 6
... 13(S)-HODE-d4 contains 4 deuterium atoms at the 9, ... for use as an internal standard for the ... 13(S)-HODE is produced by incubation of linoleic acid ... shown to inhibit the adhesion of tumor cells ...
...
...
Immunogen: Peptide corresponding to amino acid residues from the N-terminal region of human thyroid hormone receptor, alpha1/alpha2-isotype. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: